We Are Not Biotech Experts, But We Know a Big Opportunity When We See One!

We are not biotech experts, but we know how to analyze the opinions of the world's top doctors and we know a big opportunity when we see one...

The Chair of Bellus Health (BLU)'s Chronic Cough Clinical Advisory Board is Dr. Jacky Smith: click here to see for yourself. BLU is a US$1.418 BILLION market cap company making it the #1 largest chronic cough focused biotech company!

One month ago, Dr. Jacky Smith was asked about Algernon Pharmaceuticals (CSE: AGN) and its Phase 2 study of Ifenprodil for chronic cough.

Dr. Jacky Smith said on July 28th regarding AGN's Phase 2 study of Ifenprodil for chronic cough, "This additional analysis confirms my initial positive impression of the study. The NMDA receptor has always been an interesting target for cough, but other agents have been poorly tolerated. To see effects of this magnitude in an IPF population, where other drugs have failed to demonstrate a benefit, is notable, and I look forward to seeing the Company’s full data set next month."

AGN's market cap at $5.15 per share is only US$9.325 million or less than 7/10ths of 1% of BLU!

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.